Dr. Ethan Ludmir, MD

• Radiation Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic Characteristics of the Randomized Clinical Trials for COVID-19 Launched During the Pandemic, 2020-07-13

• Dosimetric uncertainties resulting from interfractional anatomic variations for patients receiving pancreas stereotactic body radiation therapy and cone-beam CT image guidance, 2021-08-13

• Disparities along the glioblastoma clinical trials landscape, 2018-11-26

• Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution, 2022-01-28

• Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases, 2021-12-15

• Evolving Practice Patterns in the Use of Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer, 2019-08-14

• Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials, 2019-11-08

• Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations, 2021-12-31

• Progression-Free Survival is a Suboptimal Predictor for Overall Survival Among Metastatic Solid Tumor Clinical Trials, 2020-07-20

• Article Processing Charge Waiver Policies as a Barrier to Oncology Scholarship in Low- and Lower-Middle-Income Countries, 2021-09-23

• Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer, 2020-03-04

• Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies Use of Clinically Interpretable End Points to Evaluate Treatment in Comparative Oncology Studies, 2023-06-21

• Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial, 2022-09-12

• Ablative Liver Radiotherapy for Unresected Intrahepatic Cholangiocarcinoma: Patterns of Care and Survival in the United States, 2022-04-13

• Impact factor and citation metrics in phase III cancer trials, 2021-08-31

• Racial and Ethnic Disparities Among Participants in US-Based Phase 3 Randomized Cancer Clinical Trials, 2020-07-07

• Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials, 2022-02-18

• Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma, 2022-04-09

• Multi-organ segmentation of abdominal structures from non-contrast and contrast enhanced CT images, 2022-11-09

• The Radiotherapy Quality Assurance Gap Among Phase III Cancer Clinical Trials, 2021-11-25

• Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials, 2020-09-16

• Food and Drug Administration approvals in phase 3 Cancer clinical trials, 2021-06-12

• Combination Intensity Modulated Proton Therapy and Passive Scatter Boost for Rapidly Progressing Nasal Cavity Squamous Cell Carcinoma, 2017-09-14

• Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma, 2021-12-01

• Assessment of Median and Mean Survival Time in Cancer Clinical Trials Assessment of Median and Mean Survival Time in Cancer Clinical Trials, 2023-04-03

• Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials, 2023-05-17

• Performance Status Restriction in Phase III Cancer Clinical Trials, 2020-10-01

• Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer, 2021-10-09

• Omitting Cardiophrenic Lymph Nodes in the Treatment of Patients with Hodgkin Lymphoma via Modified Involved-Site Radiation Therapy, 2018-04-04

• The impact of cell-of-origin, MYC/Bcl-2 Dual Expression andMYCRearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy, 2021-01-22